Anti-metastatic Properties of Naproxen-HBTA in a Murine Model of Cutaneous Melanoma.
Ontology highlight
ABSTRACT: The beneficial effects of H2S-release and of COXs-inhibition have been exploited in the design of novel anti-inflammatory drugs, the H2S-releasing non-steroidal anti-inflammatory drugs (H2S-NSAIDs), showing promising potential for chemoprevention in cancers. Here, we evaluated the efficacy of a new H2S-releasing derivative of naproxen, named naproxen-4-hydroxybenzodithioate (naproxen-HBTA), in reducing metastatic melanoma features, both in vitro and in vivo. The novel H2S donor has been prepared following a synthetic scheme that provided high yields and purity. In particular, we investigated the effect of naproxen-HBTA in vitro on several metastatic features of human melanoma cells such as proliferation, migration,
SUBMITTER: Ercolano G
PROVIDER: S-EPMC6376415 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature
ACCESS DATA